NO981528L - Substituerte imidazoler med antikreft- og cytokininhibitoraktivitet - Google Patents

Substituerte imidazoler med antikreft- og cytokininhibitoraktivitet

Info

Publication number
NO981528L
NO981528L NO981528A NO981528A NO981528L NO 981528 L NO981528 L NO 981528L NO 981528 A NO981528 A NO 981528A NO 981528 A NO981528 A NO 981528A NO 981528 L NO981528 L NO 981528L
Authority
NO
Norway
Prior art keywords
cancer
inhibitor activity
cytokine inhibitor
substituted imidazoles
atom
Prior art date
Application number
NO981528A
Other languages
English (en)
Norwegian (no)
Other versions
NO981528D0 (no
Inventor
Harold G Selnick
David A Claremon
Nigel J Liverton
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602907.9A external-priority patent/GB9602907D0/en
Priority claimed from GBGB9602975.6A external-priority patent/GB9602975D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO981528D0 publication Critical patent/NO981528D0/no
Publication of NO981528L publication Critical patent/NO981528L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO981528A 1995-10-06 1998-04-03 Substituerte imidazoler med antikreft- og cytokininhibitoraktivitet NO981528L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US506395P 1995-10-06 1995-10-06
US505995P 1995-10-06 1995-10-06
GBGB9602907.9A GB9602907D0 (en) 1996-02-13 1996-02-13 Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GBGB9602975.6A GB9602975D0 (en) 1996-02-13 1996-02-13 Acyl heterocylcic substituted imidazoles having anti-cancer and cytokine inhibitory activity
PCT/US1996/015880 WO1997012876A1 (en) 1995-10-06 1996-10-02 Substituted imidazoles having anti-cancer and cytokine inhibitory activity

Publications (2)

Publication Number Publication Date
NO981528D0 NO981528D0 (no) 1998-04-03
NO981528L true NO981528L (no) 1998-06-05

Family

ID=27451400

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981528A NO981528L (no) 1995-10-06 1998-04-03 Substituerte imidazoler med antikreft- og cytokininhibitoraktivitet

Country Status (17)

Country Link
EP (1) EP0854870B1 (et)
JP (1) JP3382951B2 (et)
KR (1) KR19990064117A (et)
CN (1) CN1117082C (et)
AT (1) ATE433446T1 (et)
AU (1) AU702146B2 (et)
CA (1) CA2234066C (et)
CZ (1) CZ292707B6 (et)
DE (1) DE69637948D1 (et)
EA (1) EA001203B1 (et)
EE (1) EE03681B1 (et)
IL (1) IL123950A (et)
NO (1) NO981528L (et)
NZ (1) NZ321738A (et)
PL (1) PL184819B1 (et)
SK (1) SK282496B6 (et)
WO (1) WO1997012876A1 (et)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
CA2250232A1 (en) * 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
EP1314732A3 (en) * 1996-12-05 2004-01-02 Amgen Inc. Substituted pyrimidine compounds and their use
IL130181A0 (en) * 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
AR038955A1 (es) * 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
KR100704059B1 (ko) 1997-06-12 2007-04-05 롱프랑 로라 리미티드 이미다졸릴-사이클릭 아세탈
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
AU8154998A (en) 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999001452A1 (en) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
CN1548436A (zh) 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ 新的2-烷基取代咪唑化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2346665A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
WO2000025791A1 (en) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
WO2000064894A1 (en) 1999-04-23 2000-11-02 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
EP1233951B1 (en) 1999-11-23 2005-06-01 SmithKline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ES2218391T3 (es) 2000-03-06 2004-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de raf-cinasa.
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
WO2001074811A2 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2001098268A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
FR2818978B1 (fr) * 2000-12-28 2003-02-28 Sod Conseils Rech Applic Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
CA2517517C (en) 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
KR101357465B1 (ko) 2006-01-31 2014-02-03 어레이 바이오파마 인크. 키나제 억제제 및 그의 사용 방법
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
AU2009227013B2 (en) * 2008-03-21 2013-01-10 Novartis Ag Novel heterocyclic compounds and uses therof
US12552768B2 (en) 2021-03-04 2026-02-17 Industry-University Cooperation Foundation Pyridinylpyrazole derivative or pharmaceutically acceptable salt thereof and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
WO1995003297A1 (en) * 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease

Also Published As

Publication number Publication date
AU7514396A (en) 1997-04-28
CZ292707B6 (cs) 2003-11-12
WO1997012876A1 (en) 1997-04-10
EA199800268A1 (ru) 1998-12-24
EP0854870B1 (en) 2009-06-10
NZ321738A (en) 1999-11-29
ATE433446T1 (de) 2009-06-15
CN1203590A (zh) 1998-12-30
CA2234066C (en) 2005-12-13
SK282496B6 (sk) 2002-02-05
NO981528D0 (no) 1998-04-03
SK43598A3 (en) 1998-11-04
EP0854870A1 (en) 1998-07-29
JPH11514353A (ja) 1999-12-07
IL123950A (en) 2001-04-30
CA2234066A1 (en) 1997-04-10
EA001203B1 (ru) 2000-12-25
EE03681B1 (et) 2002-04-15
AU702146B2 (en) 1999-02-11
CZ104398A3 (cs) 1998-07-15
EP0854870A4 (en) 1999-01-07
CN1117082C (zh) 2003-08-06
DE69637948D1 (de) 2009-07-23
PL326025A1 (en) 1998-08-17
EE9800083A (et) 1998-10-15
PL184819B1 (pl) 2002-12-31
KR19990064117A (ko) 1999-07-26
JP3382951B2 (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
NO981528L (no) Substituerte imidazoler med antikreft- og cytokininhibitoraktivitet
EP0906307A4 (en) SUBSTITUTED IMIDAZOLES WITH CYTOKININ INHIBIRING EFFECT
ATE206611T1 (de) Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung
NO985864L (no) Nye anti-virale forbindelser
DK0664126T3 (da) Hæmning af trombin
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
RU94044454A (ru) Ингибитор аутоимунных заболеваний
DE69412049D1 (de) Hemmung von dysfunctionalen Uterusblutungen
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
ATE114465T1 (de) Pharmazeutische zusammensetzung zur inhibierung der knochenresorption.
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
BR9307331A (pt) Compostos neuroprotetores 3,4-dihidro-2(1ho-quinolona
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
DK601583A (da) Carbamyloxybenzhydrolderivater
MX9802732A (es) Imidazolas substituidas que tienen actividad anticancer e inhibidora de citocina.
RU94044457A (ru) Применение бензтиофенов для ингибирования гирсутизма и алопеции у женщин
CA2257200A1 (en) Substituted imidazoles having cytokine inhibitory activity
ATE124398T1 (de) 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
KR950005921A (ko) 상처 치료를 촉진시키기 위한 조성물
KR890002222A (ko) 치매 치료제

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application